Stratification of the 457 adenocarcinoma tumors with known EGFR and KRAS mutation status into EGFR-mutated (n=113), KRAS-mutated (n=134) and EGFRwt/KRASwt (n=210) tumors revealed both common alterations across mutation groups, such as gains of chromosome 1q and 8q, and loss of 3p, and regions with apparently different prevalence between mutation groups, including gains on chromosome 7p (EGFR-mutated) and 16p (EGFR-mutated), and losses on 6q (KRAS-mutated) (Figures 2B-D). This evidence concerns the gene KRAS and adenocarcinoma.